Clinical Trial Update: Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating tamibarotene in combination with arsenic trioxide for relapsed acute promyelocytic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Tamibarotene (tamibarotene)

Snippet

Sponsor: Northwestern University | Conditions: Acute Promyelocytic Leukemia | Phase 1 | Status: TERMINATED